Molecular mechanisms underlying statin effects on genes involved in the reverse cholesterol transport

Drug Metabolism and Drug Interactions

Volumn 27, Issue 2, 2012, Pages 101-111

  Cerda, Alvaro ^a   Hirata, Mario Hiroyuki ^a   Hirata, Rosario Dominguez Crespo ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cholesterol effl ux; High density lipoprotein (HDL); Reverse cholesterol transport (RCT); Statins.

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; APOLIPOPROTEIN A1; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN; ENDOTHELIAL LIPASE; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN LIPASE; LIVER TRIACYLGLYCEROL LIPASE; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MICRORNA; N (2,2,2 TRIFLUOROETHYL) N [4 [2,2,2 TRIFLUORO 1 HYDROXY 1 (TRIFLUOROMETHOXY)ETHYL]PHENYL]BENZENESULFONAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SCAVENGER RECEPTOR BI; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1A; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; STEROL REGULATORY ELEMENT BINDING PROTEIN 2; TRIACYLGLYCEROL LIPASE; UNCLASSIFIED DRUG; CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT;

CHOLESTEROL TRANSPORT; CONFERENCE PAPER; DRUG MECHANISM; ENZYME ACTIVITY; GENE FUNCTION; HOMEOSTASIS; HUMAN; INTERNALIZATION; LIPOPROTEIN METABOLISM; NONHUMAN; PROTEIN FUNCTION; REVERSE CHOLESTEROL TRANSPORT; ANIMAL; BIOSYNTHESIS; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; HYPERCHOLESTEROLEMIA; METABOLISM; PROTEIN PROCESSING; REVIEW;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL; GENE EXPRESSION REGULATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIPOPROTEINS, HDL; MICRORNAS; PROTEIN PROCESSING, POST-TRANSLATIONAL;

EID: 84867321722     PISSN: 07925077     EISSN: None     Source Type: Journal    
DOI: 10.1515/dmdi-2012-0007     Document Type: Conference Paper

References (95)

1. Vaughan CJ, Gotto AM Jr. Update on statins: 2003. Circulation 2004;110:886-92. (Pubitemid 39096019)
2. Pedersen TR. Pleiotropic effects of statins: evidence against benefi ts beyond LDL-cholesterol lowering. Am J Cardiovasc Drugs 2010;10:Suppl 1:10-7.
3. Aviram M, Rosenblat M. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Free Radic Biol Med 2004;37:1304-16. (Pubitemid 39349234)
4. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;96:1221-32. (Pubitemid 40962099)
5. Trigatti BL, Krieger M, Rigotti A. Infl uence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:1732-8. (Pubitemid 37254855)
6. Sato R. Sterol metabolism and SREBP activation. Arch Biochem Biophys 2010;501:177-81.
7. Forman BM, Ruan B, Chen J, Schroepfer GJ, Jr., Evans RM. The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA 1997;94:10588-93.
8. Balakumar P, Arora MK, Singh M. Emerging role of PPAR ligands in the management of diabetic nephropathy. Pharmacol Res 2009;60:170-3.
9. Balakumar P, Rose M, Ganti SS, Krishan P, Singh M. PPAR dual agonists: are they opening Pandora's Box? Pharmacol Res 2007;56:91-8. (Pubitemid 47304493)
10. Balakumar P, Mahadevan N. Interplay between statins and PPARs in improving cardiovascular outcomes: a double-edged sword? Br J Pharmacol 2012;165:373-9.
11. Genvigir FD, Rodrigues AC, Cerda A, Arazi SS, Willrich MA, Oliveira R, et al. Effects of lipid-lowering drugs on reverse cholesterol transport gene expressions in peripheral blood mononuclear and HepG2 cells. Pharmacogenomics 2010;11: 1235-46.
12. Ando H, Tsuruoka S, Yamamoto H, Takamura T, Kaneko S, Fujimura A. Effects of pravastatin on the expression of ATP-binding cassette transporter A1. J Pharmacol Exp Ther 2004;311:420-5. (Pubitemid 39287824)
13. Sone H, Shimano H, Shu M, Nakakuki M, Takahashi A, Sakai M, et al. Statins downregulate ATP-binding-cassette transporter A1 gene expression in macrophages. Biochem Biophys Res Commun 2004;316:790-4. (Pubitemid 38368021)
14. Llaverias G, Rebollo A, Pou J, Vazquez-Carrera M, Sanchez RM, Laguna JC, et al. Effects of rosiglitazone and atorvastatin on the expression of genes that control cholesterol homeostasis in differentiating monocytes. Biochem Pharmacol 2006;71:605-14. (Pubitemid 43121994)
15. Wong J, Quinn CM, Gelissen IC, Jessup W, Brown AJ. The effect of statins on ABCA1 and ABCG1 expression in human macrophages is infl uenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis 2008;196:180-9.
16. Guan JZ, Tamasawa N, Murakami H, Matsui J, Tanabe J, Matsuki K, et al. HMG-CoA reductase inhibitor, simvastatin improves reverse cholesterol transport in type 2 diabetic patients with hyperlipidemia. J Atheroscler Thromb 2008;15:20-5.
17. Zanotti I, Favari E, Sposito AC, Rothblat GH, Bernini F. Pitavastatin increases ABCA1-mediated lipid effl ux from Fu5AH rat hepatoma cells. Biochem Biophys Res Commun 2004;321:670-4. (Pubitemid 39118390)
18. Kobayashi M, Gouda K, Chisaki I, Ochiai M, Itagaki S, Iseki K. Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol 2011;662:9-14.
19. Maejima T, Sugano T, Yamazaki H, Yoshinaka Y, Doi T, Tanabe S, et al. Pitavastatin increases ABCA1 expression by dual mechanisms: SREBP2-driven transcriptional activation and PPARalpha-dependent protein stabilization but without activating LXR in rat hepatoma McARH7777 cells. J Pharmacol Sci 2011;116:107-15.
20. Tamehiro N, Shigemoto-Mogami Y, Kakeya T, Okuhira K, Suzuki K, Sato R, et al. Sterol regulatory element-binding protein-2- and liver X receptor-driven dual promoter regulation of hepatic ABC transporter A1 gene expression: mechanism underlying the unique response to cellular cholesterol status. J Biol Chem 2007;282:21090-9. (Pubitemid 47099939)
21. Song G, Liu J, Zhao Z, Yu Y, Tian H, Yao S, et al. Simvastatin reduces atherogenesis and promotes the expression of hepatic genes associated with reverse cholesterol transport in apoEknockout mice fed high-fat diet. Lipids Health Dis 2011;10:8.
22. Genvigir FD, Rodrigues AC, Cerda A, Hirata MH, Curi R, Hirata RD. ABCA1 and ABCG1 expressions are regulated by statins and ezetimibe in Caco-2 cells. Drug Metabol Drug Interact 2011;26:33-6.
23. Cerda A, Genvigir FD, Rodrigues AC, Willrich MA, Dorea EL, Bernik MM, et al. Infl uence of polymorphisms and cholesterollowering treatment on SCARB1 mRNA expression. J Atheroscler Thromb 2011;18:640-51.
24. Kimura T, Mogi C, Tomura H, Kuwabara A, Im DS, Sato K, et al. Induction of scavenger receptor class B type I is critical for simvastatin enhancement of high-density lipoproteininduced anti-infl ammatory actions in endothelial cells. J Immunol 2008;181:7332-40.
25. Martin G, Duez H, Blanquart C, Berezowski V, Poulain P, Fruchart JC, et al. Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I. J Clin Invest 2001;107:1423-32. (Pubitemid 32522036)
26. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, et al. Effect of pitavastatin on apolipoprotein A-I production in HepG2 cell. Biochem Biophys Res Commun 2004;324: 835-9. (Pubitemid 39345591)
27. Qin S, Koga T, Ganji SH, Kamanna VS, Kashyap ML. Rosuvastatin selectively stimulates apolipoprotein A-I but not apolipoprotein A-II synthesis in Hep G2 cells. Metabolism 2008;57:973-9. (Pubitemid 351814690)
28. Kassai A, Illyes L, Mirdamadi HZ, Seres I, Kalmar T, Audikovszky M, et al. The effect of atorvastatin therapy on lecithin:cholesterol acyltransferase, cholesteryl ester transfer protein and the antioxidant paraoxonase. Clin Biochem 2007;40:1-5. (Pubitemid 46014148)
29. Kawano M, Nagasaka S, Yagyu H, Ishibashi S. Pitavastatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb 2008;15:41-6.
30. Vaziri ND, Liang K. Effects of HMG-CoA reductase inhibition on hepatic expression of key cholesterol-regulatory enzymes and receptors in nephrotic syndrome. Am J Nephrol 2004;24:606-13. (Pubitemid 40187018)
31. Liang K, Kim CH, Vaziri ND. HMG-CoA reductase inhibition reverses LCAT and LDL receptor defi ciencies and improves HDL in rats with chronic renal failure. Am J Physiol Renal Physiol 2005;288:F539-44. (Pubitemid 40279460)
32. Sviridov D, Hoang A, Ooi E, Watts G, Barrett PH, Nestel P. Indices of reverse cholesterol transport in subjects with metabolic syndrome after treatment with rosuvastatin. Atherosclerosis 2008;197:732-9. (Pubitemid 351417870)
33. de Vries R, Kerstens MN, Sluiter WJ, Groen AK, van Tol A, Dullaart RP. Cellular cholesterol effl ux to plasma from moderately hypercholesterolaemic type 1 diabetic patients is enhanced, and is unaffected by simvastatin treatment. Diabetologia 2005;48:1105-13. (Pubitemid 40909645)
34. van Venrooij FV, Stolk RP, Banga JD, Sijmonsma TP, van Tol A, Erkelens DW, et al. Common cholesteryl ester transfer protein gene polymorphisms and the effect of atorvastatin therapy in type 2 diabetes. Diabetes Care 2003;26:1216-23. (Pubitemid 36929275)
35. de Haan W, van der Hoogt CC, Westerterp M, Hoekstra M, Dallinga-Thie GM, Princen HM, et al. Atorvastatin increases HDL cholesterol by reducing CETP expression in cholesterol-fed APOE*3-Leiden.CETP mice. Atherosclerosis 2008;197:57-63. (Pubitemid 351273273)
36. Endo K, Miyashita Y, Saiki A, Oyama T, Koide N, Ozaki H, et al. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb 2004;11:341-7.
37. Schneider JG, von Eynatten M, Parhofer KG, Volkmer JE, Schiekofer S, Hamann A, et al. Atorvastatin improves diabetic dyslipidemia and increases lipoprotein lipase activity in vivo. Atherosclerosis 2004;175:325-31. (Pubitemid 38942913)
38. Qiu G, Hill JS. Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages. J Lipid Res 2007;48:2112-22. (Pubitemid 47529554)
39. Llaverias G, Pou J, Ros E, Zambon D, Cofan M, Sanchez A, et al. Monocyte gene-expression profi le in men with familial combined hyperlipidemia and its modifi cation by atorvastatin treatment. Pharmacogenomics 2008;9:1035-54.
40. Berk P, II, Hoogerbrugge N, Stolk RP, Bootsma AH, Jansen H. Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant. Diabetes Care 2003;26:427-32. (Pubitemid 36929067)
41. Kojima Y, Ishida T, Sun L, Yasuda T, Toh R, Rikitake Y, et al. Pitavastatin decreases the expression of endothelial lipase both in vitro and in vivo. Cardiovasc Res 2010;87:385-93.
42. Vedhachalam C, Duong PT, Nickel M, Nguyen D, Dhanasekaran P, Saito H, et al. Mechanism of ATP-binding cassette transporter A1-mediated cellular lipid effl ux to apolipoprotein A-I and formation of high density lipoprotein particles. J Biol Chem 2007;282:25123-30. (Pubitemid 47347535)
43. Seo M, Inoue I, Ikeda M, Nakano T, Takahashi S, Katayama S, et al. Statins Activate Human PPARalpha Promoter and Increase PPARalpha mRNA Expression and Activation in HepG2 Cells. PPAR Res 2008 (Article ID: 316306):1-11.
44. Ogata M, Tsujita M, Hossain MA, Akita N, Gonzalez FJ, Staels B, et al. On the mechanism for PPAR agonists to enhance ABCA1 gene expression. Atherosclerosis 2009;205:413-9.
45. Marquart TJ, Allen RM, Ory DS, Baldan A. miR-33 links SREBP-2 induction to repression of sterol transporters. Proc Natl Acad Sci USA 2010;107:12228-32.
46. Wong J, Quinn CM, Brown AJ. Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol fl ux. Arterioscler Thromb Vasc Biol 2004;24:2365-71. (Pubitemid 39658043)
47. Argmann CA, Edwards JY, Sawyez CG, O'Neil CH, Hegele RA, Pickering JG, et al. Regulation of macrophage cholesterol effl ux through hydroxymethylglutaryl- CoA reductase inhibition: a role for RhoA in ABCA1-mediated cholesterol effl ux. J Biol Chem 2005;280:22212-21. (Pubitemid 40827878)
48. Genvigir FD, Hirata MH, Hirata RD. ABCA1 expression and statins: inhibitory effect in peripheral blood mononuclear cells. Pharmacogenomics 2009;10:997-1005.
49. Kruit JK, Groen AK, van Berkel TJ, Kuipers F. Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 2006;12:6429-39. (Pubitemid 44742578)
50. Murthy S, Born E, Mathur SN, Field FJ. LXR/RXR activation enhances basolateral effl ux of cholesterol in CaCo-2 cells. J Lipid Res 2002;43:1054-64. (Pubitemid 34760876)
51. Field FJ, Born E, Mathur SN. Stanol esters decrease plasma cholesterol independently of intestinal ABC sterol transporters and Niemann-Pick C1-like 1 protein gene expression. J Lipid Res 2004;45:2252-9. (Pubitemid 39602972)
52. Lee J, Hong EM, Koh DH, Choi MH, Jang HJ, Kae SH, et al. HMG-CoA reductase inhibitors (statins) activate expression of PPARalpha/PPARgamma and ABCA1 in cultured gallbladder epithelial cells. Dig Dis Sci 2010;55:292-9.
53. Tall AR, Yvan-Charvet L, Terasaka N, Pagler T, Wang N. HDL, ABC transporters, and cholesterol effl ux: implications for the treatment of atherosclerosis. Cell Metab 2008;7:365-75. (Pubitemid 351598023)
54. Jiang YJ, Lu B, Tarling EJ, Kim P, Man MQ, Crumrine D, et al. Regulation of ABCG1 expression in human keratinocytes and murine epidermis. J Lipid Res 2010;51:3185-95.
55. Schmitz G, Langmann T. High-density lipoproteins and ATPbinding cassette transporters as targets for cardiovascular drug therapy. Curr Opin Investig Drugs 2005;6:907-19. (Pubitemid 41269371)
56. Rhainds D, Brodeur M, Lapointe J, Charpentier D, Falstrault L, Brissette L. The role of human and mouse hepatic scavenger receptor class B type I (SR-BI) in the selective uptake of low-density lipoprotein-cholesteryl esters. Biochemistry 2003;42:7527-38. (Pubitemid 36735830)
57. Van Eck M, Hoekstra M, Out R, Bos IS, Kruijt JK, Hildebrand RB, et al. Scavenger receptor BI facilitates the metabolism of VLDL lipoproteins in vivo. J Lipid Res 2008;49:136-46.
58. Han J, Parsons M, Zhou X, Nicholson AC, Gotto AM, Jr., Hajjar DP. Functional interplay between the macrophage scavenger receptor class B type I and pitavastatin (NK-104). Circulation 2004;110:3472-9. (Pubitemid 39602226)
59. Zhao SP, Wu ZH, Hong SC, Ye HJ, Wu J. Effect of atorvastatin on SR-BI expression and HDL-induced cholesterol effl ux in adipocytes of hypercholesterolemic rabbits. Clin Chim Acta 2006;365:119-24. (Pubitemid 43196426)
60. Krimbou L, Marcil M, Genest J. New insights into the biogenesis of human high-density lipoproteins. Curr Opin Lipidol 2006;17:258-67. (Pubitemid 43786059)
61. Hiro T, Kimura T, Morimoto T, Miyauchi K, Nakagawa Y, Yamagishi M, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS [Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome] study). J Am Coll Cardiol 2009;54:293-302.
62. Mauger JF, Couture P, Paradis ME, Lamarche B. Comparison of the impact of atorvastatin and simvastatin on apoA-I kinetics in men. Atherosclerosis 2005;178:157-63. (Pubitemid 39600828)
63. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther 2008;30:1089-101. (Pubitemid 351978115)
64. Teramoto T, Shimano H, Yokote K, Urashima M. Effects of pitavastatin (LIVALO Tablet) on high density lipoprotein cholesterol (HDL-C) in hypercholesterolemia. J Atheroscler Thromb 2009;16:654-61.
65. Schuster H. Rosuvastatin - a highly effective new 3-hydroxy- 3-methylglutaryl coenzyme A reductase inhibitor: review of clinical trial data at 10-40 mg doses in dyslipidemic patients. Cardiology 2003;99:126-39. (Pubitemid 36736955)
66. Blanco-Vaca F, Escola-Gil JC, Martin-Campos JM, Julve J. Role of apoA-II in lipid metabolism and atherosclerosis: advances in the study of an enigmatic protein. J Lipid Res 2001;42:1727-39. (Pubitemid 33116704)
67. Chan DC, Ng TW, Watts GF. Apolipoprotein A-II: evaluating its signifi cance in dyslipidaemia, insulin resistance, and atherosclerosis. Ann Med 2012;44:313-24.
68. Briand F, Magot T, Krempf M, Nguyen P, Ouguerram K. Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. Eur J Clin Invest 2006;36:224-30.
69. Jonas A. Regulation of lecithin cholesterol acyltransferase activity. Prog Lipid Res 1998;37:209-34. (Pubitemid 28421192)
70. Mitka M. CETP inhibition shows promise as way to reduce cardiovascular disease risk. J Am Med Assoc 2011;305:136-7.
71. Caslake MJ, Stewart G, Day SP, Daly E, McTaggart F, Chapman MJ, et al. Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia. Atherosclerosis 2003;171:245-53. (Pubitemid 37486076)
72. Masson D, Staels B, Gautier T, Desrumaux C, Athias A, Le Guern N, et al. Cholesteryl ester transfer protein modulates the effect of liver X receptor agonists on cholesterol transport and excretion in the mouse. J Lipid Res 2004;45:543-50. (Pubitemid 38338001)
73. Clee SM, Bissada N, Miao F, Miao L, Marais AD, Henderson HE, et al. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. J Lipid Res 2000;41:521-31. (Pubitemid 30220655)
74. Schoonjans K, Gelman L, Haby C, Briggs M, Auwerx J. Induction of LPL gene expression by sterols is mediated by a sterol regulatory element and is independent of the presence of multiple E boxes. J Mol Biol 2000;304:323-34.
75. Leiva A, Verdejo H, Benitez ML, Martinez A, Busso D, Rigotti A. Mechanisms regulating hepatic SR-BI expression and their impact on HDL metabolism. Atherosclerosis 2011;217: 299-307.
76. Lopez D, McLean MP. Activation of the rat scavenger receptor class B type I gene by PPARalpha. Mol Cell Endocrinol 2006;251:67-77. (Pubitemid 43728841)
77. Malerod L, Sporstol M, Juvet LK, Mousavi A, Gjoen T, Berg T. Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha. Biochem Biophys Res Commun 2003;305:557-65. (Pubitemid 36579267)
78. Malerod L, Juvet LK, Hanssen-Bauer A, Eskild W, Berg T. Oxysterol-activated LXRalpha/RXR induces hSR-BI-promoter activity in hepatoma cells and preadipocytes. Biochem Biophys Res Commun 2002;299:916-23. (Pubitemid 36034574)
79. Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell 2009;136:215-33.
80. Fernandez-Hernando C, Suarez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Curr Opin Lipidol 2011; 22:86-92.
81. Esau C, Davis S, Murray SF, Yu XX, Pandey SK, Pear M, et al. miR-122 regulation of lipid metabolism revealed by in vivo antisense targeting. Cell Metab 2006;3:87-98.
82. Iliopoulos D, Drosatos K, Hiyama Y, Goldberg IJ, Zannis VI. MicroRNA-370 controls the expression of microRNA- 122 and Cpt1alpha and affects lipid metabolism. J Lipid Res 2010;51:1513-23.
83. Kajimoto K, Naraba H, Iwai N. MicroRNA and 3T3-L1 pre-adipocyte differentiation. RNA 2006;12:1626-32. (Pubitemid 44316027)
84. Gerin I, Bommer GT, McCoin CS, Sousa KM, Krishnan V, MacDougald OA. Roles for miRNA-378/378*in adipocyte gene expression and lipogenesis. Am J Physiol Endocrinol Metab 2010;299:E198-206.
85. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, et al. MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004;279:52361-5. (Pubitemid 39656612)
86. Lin Q, Gao Z, Alarcon RM, Ye J, Yun Z. A role of miR-27 in the regulation of adipogenesis. FEBS J 2009;276:2348-58.
87. Ling HY, Wen GB, Feng SD, Tuo QH, Ou HS, Yao CH, et al. MicroRNA-375 promotes 3T3-L1 adipocyte differentiation through modulation of extracellular signal-regulated kinase signalling. Clin Exp Pharmacol Physiol 2011;38:239-46.
88. Parra P, Serra F, Palou A. Expression of adipose microRNAs is sensitive to dietary conjugated linoleic acid treatment in mice. PLoS One 2010;5:e13005.
89. Gerin I, Clerbaux LA, Haumont O, Lanthier N, Das AK, Burant CF, et al. Expression of miR-33 from an SREBP2 intron inhibits cholesterol export and fatty acid oxidation. J Biol Chem 2010;285:33652-61.
90. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, et al. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328:1570-3.
91. Najafi -Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-9.
92. Horie T, Ono K, Horiguchi M, Nishi H, Nakamura T, Nagao K, et al. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 2010;107:17321-6.
93. Ho PC, Chang KC, Chuang YS, Wei LN. Cholesterol regulation of receptor-interacting protein 140 via microRNA-33 in infl ammatory cytokine production. FASEB J 2011;25:1758-66.
94. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10. (Pubitemid 47481452)
95. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 2008;15:52-62.